
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is poised to make a major impact in the biotechnology industry with its innovative approach to targeting the Wnt pathway for tissue repair. With promising preclinical results for its lead drug candidate, SZN-8141, and a strong pipeline of other Wnt-based therapeutics, the company has the potential to become a leader in the treatment of retinal diseases. Additionally, the recent positive outcome from its partnership with Boehringer Ingelheim highlights the company's strong potential for growth and development. Investors can expect continued progress and potential market differentiation as Surrozen advances towards IND submission and initiation of clinical trials for its lead drug candidate.
Bears say
Surrozen is a clinical-stage biotechnology company currently facing risks to its investment thesis, including failure to secure adequate funding for operations and uncertain commercial success of its developmental candidates in the competitive biopharmaceutical market. The company's financials for 1Q26 showed negative earnings per share and a net loss, signaling potential financial instability. Its product candidate, SZN-8141, may offer a potential advantage due to its bifunctional Wnt/VEGF antibody design, but the company's overall outlook remains uncertain.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares